Allergan
Allergan, a wholly-owned AbbVie subsidiary since 2020, is a global specialty pharmaceutical and medical aesthetics company offering BOTOX, the JUVÉDERM filler collection, and eye care products to healthcare providers, aesthetic clinics, dermatologists, and ophthalmologists worldwide.
- Company typePrivate
- Founded1950
- HeadquartersMadison, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Allergan does
Allergan, originally founded in 1950 as a small eye-care company, operated as a global specialty pharmaceutical and medical aesthetics company before being acquired by AbbVie in March 2020 for approximately $63 billion. Pre-acquisition, under David Pyott's 17-year tenure, Allergan grew from approximately $1 billion in revenue to approximately $7 billion by expanding into aesthetics, eye care, immunology, and oncology products. Today Allergan is a wholly-owned subsidiary of AbbVie, operating under the Allergan Aesthetics and Allergan Eye Care brands within a combined organization of approximately 50,000 employees.
Allergan's product portfolio centers on BOTOX, the original botulinum toxin type A product that pioneered the medical aesthetics industry, and the JUVÉDERM collection of FDA-approved hyaluronic acid injectable dermal fillers used for facial volume restoration, wrinkle smoothing, and lip enhancement, with the September 2023-launched SKINVIVE by JUVÉDERM extending the franchise. The broader portfolio spans over 30 brands treating more than 60 conditions across oncology, immunology, aesthetics, and eye care. Distribution relies on an enterprise field sales model reaching aesthetic clinics, dermatology centers, ophthalmology practices, spasticity treatment providers, and hospitals globally.
Revenue is generated through one-time license/injection-based transactions administered by licensed healthcare providers. JUVÉDERM fillers are priced at approximately $450-$650 per syringe in the United States with results lasting 6 to 18 months per treatment cycle. Allergan plc was Irish-domiciled prior to the acquisition; Allergan Sales, LLC operates as a US subsidiary for legal and commercial purposes. The company has engaged in active patent litigation and defense (Restasis, eyelash growth drug, Botox-related disputes) and most recently terminated a February 2021 development agreement with CollPlant Biotechnologies for a photocurable dermal filler in April 2026.
Allergan firmographics
Firmographics- Name
- Allergan
- Legal name
- Allergan plc
- Website
- https://allergan.com
- Company type
- Private
- Founded year
- 1950
- Operating status
- Acquired
- Headcount range
- 5,001–10,000 employees
- Short description
- Allergan, a wholly-owned AbbVie subsidiary since 2020, is a global specialty pharmaceutical and medical aesthetics company offering BOTOX, the JUVÉDERM filler collection, and eye care products to healthcare providers, aesthetic clinics, dermatologists, and ophthalmologists worldwide.
- Ownership category
- akta.pro rank
Allergan industry classification
Industry- Product category
- Specialty Pharmaceuticals and Medical Aesthetics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
Keywords
Where Allergan is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Allergan business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Pharmaceutical Products: Revenue from prescription pharmaceutical products across multiple therapeutic areas including immunology, oncology, aesthetics, and eye care, with over 30+ brands treating 60+ conditions
- Medical Aesthetics: Revenue from aesthetic products including BOTOX, JUVÉDERM fillers, and other aesthetic devices and treatments
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | JUVÉDERM injectable dermal fillers - per syringe pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Allergan product offering
Product offeringCore offering
Allergan, now part of AbbVie, develops and commercializes pharmaceutical and medical aesthetics products across more than 30 brands treating over 60 conditions. Its portfolio centers on botulinum toxin (BOTOX), hyaluronic acid dermal fillers (JUVÉDERM collection including SKINVIVE by JUVÉDERM), specialty medicines in immunology and oncology, and ophthalmology treatments, sold to healthcare providers, aesthetic clinics, and hospitals globally.
Product overview
Allergan, now part of AbbVie, offers over 30+ brands treating 60+ conditions across oncology, immunology, aesthetics, and eye care. The company's aesthetics portfolio centers on its iconic Botox franchise and the Juvéderm collection of hyaluronic acid dermal fillers, including the recently FDA-approved SKINVIVE by JUVÉDERM.
Differentiator
Problem solved
Functional benefit
Brands
- JUVÉDERM: FDA-approved injectable dermal fillers collection made with hyaluronic acid to restore facial volume, smooth wrinkles, and enhance lips. Multiple formulations tailored for different facial areas with results lasting 6 to 18 months.
- BOTOX
- BOTOX Cosmetic
Products and services
- BOTOX
- JUVÉDERM Collection
- SKINVIVE by JUVÉDERM
- BOTOX Cosmetic
Companies that use Allergan
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Allergan technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Allergan partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- CollPlant BiotechnologiesminorDevelopment and global commercialization agreement for dermal and soft tissue filler products using CollPlant's photocurable dermal filler platform. AbbVie through its subsidiary Allergan Industrie SAS terminated this agreement in April 2026, leading CollPlant to implement cost-reduction measures including approximately 50% workforce reduction.
- Various Generic Pharmaceutical CompaniesminorAllergan has been involved in patent litigation defending its drug portfolios including the use of tribal immunity strategies, as documented in DrugPatentWatch analysis of pharmaceutical patent litigation costs.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Allergan competitors and assessment
Company assessmentEmerging players
- Prollenium Medical Technologies:
- Crown Laboratories: Crown Laboratories (with its SkinMedica brand) competes in the medical aesthetics and professional skincare space, offering complementary skin rejuvenation treatments alongside Allergan's aesthetics portfolio.
- Hugel: Hugel is a South Korea-based botulinum toxin manufacturer (Botulax/Letybo) expanding globally as a lower-priced competitor to BOTOX in aesthetics and therapeutics — emerging as a meaningful threat in price-sensitive markets.
Direct peers
- Galderma: Galderma is the leading direct competitor to Allergan Aesthetics, marketing the Dysport botulinum toxin, Restylane hyaluronic acid fillers, and Sculptra — directly contesting BOTOX and JUVÉDERM in aesthetic clinics worldwide.
- Revance Therapeutics: Revance developed DaxibotulinumtoxinA (Daxxify), a long-duration neuromodulator, and the RHA Collection of hyaluronic acid fillers — directly competing with both BOTOX and JUVÉDERM in medical aesthetics.
- Evolus: Evolus markets Jeuveau (prabotulinumtoxinA), a competing botulinum toxin type A approved for glabellar lines, directly targeting Allergan's BOTOX Cosmetic in the aesthetics channel.
- Merz Aesthetics: Merz Aesthetics competes head-to-head with Allergan in medical aesthetics, offering Xeomin (botulinum toxin), the Radiesse and Belotero filler lines, and Ultherapy — a direct portfolio overlap in both toxins and dermal fillers.
- Ipsen: Ipsen manufactures Dysport (abobotulinumtoxinA), a leading competitor to BOTOX in both aesthetic and therapeutic indications (spasticity, cervical dystonia), and partners with Galderma for aesthetics distribution.
Broad incumbents
- AbbVie: AbbVie is Allergan's parent company and the broad incumbent acquirer that consolidates Allergan's aesthetics and eye care franchises alongside Humira, Skyrizi, and Rinvoq in immunology and oncology.
Others
- Teva Pharmaceutical Industries: Teva acquired Allergan's Actavis Generics unit for $40.5B in 2015, creating a former corporate relationship; Teva remains a peer in the broader specialty and generics pharmaceutical landscape.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Allergan social profiles
Digital presenceAllergan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allergan leadership team
Management profileNumber of profiles
Allergan subsidiaries and ownership
Company hierarchySubsidiaries3 records
Allergan funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allergan M&A and investment
M&A and investmentM&A31 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allergan
What does Allergan do?
Allergan, now part of AbbVie, develops and commercializes pharmaceutical and medical aesthetics products across more than 30 brands treating over 60 conditions. Its portfolio centers on botulinum toxin (BOTOX), hyaluronic acid dermal fillers (JUVÉDERM collection including SKINVIVE by JUVÉDERM), specialty medicines in immunology and oncology, and ophthalmology treatments, sold to healthcare providers, aesthetic clinics, and hospitals globally.
Is Allergan a public or private company?
Allergan is a private company. It is classified as corporate owned and is currently acquired.
When was Allergan founded?
Allergan was founded in 1950. It employs 5,001 to 10,000 people.
Where is Allergan based?
Allergan is headquartered in Madison, United States, in the North America region.
How does Allergan make money?
Two revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Aesthetics.
Who are Allergan's main competitors?
Emerging players on record are Prollenium Medical Technologies, Crown Laboratories and Hugel. Direct peers are Galderma, Revance Therapeutics, Evolus, Merz Aesthetics and Ipsen. AbbVie is listed as a broad incumbent. Teva Pharmaceutical Industries is listed as an others.
Does Allergan have an API?
No public API is recorded for Allergan.
What industry is Allergan in?
Allergan's product category is Specialty Pharmaceuticals and Medical Aesthetics. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 325412 and its SIC code is 2834.